DRKS00025316已完成不适用
Immunogenicity according to reactogenicity of Covid-19 vaccines
niversitätsklinikum Regensburg0 个研究点目标入组 90 人开始时间: 2021年5月12日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 90
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 Years 至 one（—）
- 性别
- All
入选标准
- •o minimum age 18 years
- •o two doses of BNT 162b2 at intervals of 3-6 weeks o 2nd dose 4-10 weeks before enrolment
- •o informed consent
排除标准
- •o no informed consent
- •o no willingness to complete the survey
- •o no history of covid-19
研究者
相似试验
Enrolling By Invitation
不适用
Follow-up: Immunogenicity according to reactogenicity of Covid-19 vaccinesReactogenicity and immunogenicity of ComirnatyDRKS00026982niversity Medical Center Regensburg76
尚未招募
4 期
Mixing of COVID vaccines studyCTRI/2021/08/035648Christian Medical College
招募中
4 期
Evaluation of immunogenicity and reactogenicity of heterologous covid-19 vaccine combination ChAdOx-1S followed by BNT162b2prevention covidDRKS00025271niklinik Regensburg Abteilung für Hygiene und Infektiologie154
进行中（未招募）
1 期
The 6-in-1 Vaccine StudyEUCTR2018-003451-38-GBClinical Trials and Research Governance (CTRG)240
进行中（未招募）
不适用
Immunogenicity and reactogenicity of the trivalent influenza subunit vaccine Influvac® for the season 2006/2007. An open, baseline-controlled study in two groups of healthy subjects: adult subjects greater than or equal to 18 and less than or equal 60 years and elderly subjects greater than or equal to 61 years of age. - Influvac annual update 2006Prophylaxis of influenza, especially in those who run an increased risk of associated complications.EUCTR2006-001300-37-DESolvay Pharmaceuticals B.V.120